Merck & Co., US58933Y1055

Merck & Co. stock: Phase 3 drug trial meets survival goal

Published on 11/20/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock is in focus after sac-TMT improved overall survival in a global trial. Progression-free survival was not met, leaving regulators to assess the data.

Merck advances oncology pipeline

  • Merck said the TroFuse-015 study met its primary overall survival endpoint in heavily pretreated gastroesophageal cancer.
  • The study enrolled 473 patients, while progression-free survival was not met as a secondary endpoint.
  • Merck plans to present the findings at a medical meeting and discuss them with regulators.
Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck said on Friday, November 20, 2026, that its investigational cancer drug sacituzumab tirumotecan, or sac-TMT, met the primary overall survival endpoint in the global Phase 3 TroFuse-015 trial. The company said the study showed a statistically significant and clinically meaningful improvement against treatment chosen by physicians.

The announcement comes from Merck. TroFuse-015 evaluated sac-TMT in patients with locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two earlier lines of systemic therapy.

Survival benefit with limitations

The trial enrolled 473 patients who received either sac-TMT or treatment of physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Merck said the overall survival result was generally consistent across subgroups, regardless of TROP2 expression.

The drug did not meet the secondary endpoint of progression-free survival assessed by blinded independent central review. Objective response rate nominally favored sac-TMT, but Merck said that result was not formally tested under the prespecified analysis plan. The company reported no new safety signals.

Regulatory steps remain ahead

Merck said the findings will be presented at an upcoming medical meeting and shared with regulatory authorities. Sac-TMT is an investigational TROP2-directed antibody-drug conjugate licensed from Kelun-Biotech, and the TroFuse program is evaluating it across 18 global Phase 3 studies.

For investors, the result adds a positive late-stage oncology readout while the missed progression-free survival endpoint leaves the full clinical and regulatory assessment open. Merck & Co. stock traded at 124.56 euros on Lang & Schwarz at 16:08:30 CET on Friday, November 20, 2026.

Merck & Co. profile

  • Company: Merck & Co., Inc.
  • ISIN: US58933Y1055
  • Lang & Schwarz quote: 124.56 euros on November 20, 2026, at 16:08:30 CET
  • Research result: TroFuse-015 met its overall survival endpoint

In the broader US equity market, investors can follow current market reports.

More news and analyses on Merck & Co. stock

Disclaimer...
en | US58933Y1055 | MERCK & CO. | boerse | 70540392 | bgmi